Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1984 1
1989 1
1992 1
1994 1
1995 1
1996 3
1997 1
1998 3
1999 2
2000 6
2001 3
2002 4
2003 10
2004 28
2005 29
2006 25
2007 35
2008 33
2009 33
2010 40
2011 76
2012 92
2013 92
2014 107
2015 122
2016 111
2017 99
2018 62
2019 65
2020 49
2021 42
2022 31
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23918733

1,062 results

Results by year

Filters applied: . Clear all
Page 1
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P. Thureau S, et al. J Nucl Med. 2013 Sep;54(9):1543-50. doi: 10.2967/jnumed.112.118083. Epub 2013 Aug 5. J Nucl Med. 2013. PMID: 23918733 Free article. Clinical Trial.
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, Ménard JF, Modzelewski R, Thiberville L, Dubray B. Vera P, et al. Radiother Oncol. 2011 Jan;98(1):109-16. doi: 10.1016/j.radonc.2010.10.011. Epub 2010 Nov 4. Radiother Oncol. 2011. PMID: 21056487
Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J, Li C, Hu M, Lu J, Shi X, Xing L, Sun X, Fu Z, Yu J, Meng X. Liu J, et al. Medicine (Baltimore). 2015 May;94(17):e678. doi: 10.1097/MD.0000000000000678. Medicine (Baltimore). 2015. PMID: 25929896 Free PMC article.
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C. Kahraman D, et al. J Nucl Med. 2011 Dec;52(12):1871-7. doi: 10.2967/jnumed.111.094458. Epub 2011 Nov 7. J Nucl Med. 2011. PMID: 22065872 Free article. Clinical Trial.
1,062 results